Castle Biosciences Stock Investor Sentiment

CSTL Stock  USD 30.28  0.16  0.53%   
About 67% of Castle Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Castle Biosciences suggests that many traders are alarmed. Castle Biosciences' investing sentiment shows overall attitude of investors towards Castle Biosciences.
  

Castle Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Castle Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three weeks ago at thelincolnianonline.com         
Disposition of 934 shares by Derek Maetzold of Castle Biosciences at 32.528 subject to Rule 16b-3
news
over three weeks ago at businesswire.com         
Use of Castle Biosciences DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures...
businesswire News
over three weeks ago at businesswire.com         
Use of Castle Biosciences DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures...
businesswire News
over three weeks ago at thelincolnianonline.com         
Scotiabank Increases Castle Biosciences Price Target to 44.00
news
over three weeks ago at finance.yahoo.com         
Use of Castle Biosciences DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures...
Yahoo News
over three weeks ago at finance.yahoo.com         
Castle Biosciences Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over three weeks ago at investing.com         
Castle Biosciences director Daniel Bradbury sells 273,251 in stock
Investing News at Macroaxis
over three weeks ago at investing.com         
Disposition of 3507 shares by Tobin Juvenal of Castle Biosciences at 3.38 subject to Rule 16b-3
Investing News at Macroaxis
over three weeks ago at investing.com         
Castle Biosciences chief commercial officer sells 109,709 in stock
Investing News at Macroaxis
over three weeks ago at insidermonkey.com         
Castle Biosciences, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
Castle Biosciences Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ...
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Castle Biosciences Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ...
Yahoo News
over three weeks ago at thelincolnianonline.com         
KeyCorp Issues Positive Forecast for Castle Biosciences Stock Price
news
over three weeks ago at businesswire.com         
Castle Biosciences Reports Third Quarter 2024 Results
businesswire News
over three weeks ago at zacks.com         
Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 33.155 subject to Rule 16b...
zacks News
Far too much social signal, news, headlines, and media speculation about Castle Biosciences that are available to investors today. That information is available publicly through Castle media outlets and privately through word of mouth or via Castle internal channels. However, regardless of the origin, that massive amount of Castle data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Castle Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Castle Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Castle Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Castle Biosciences alpha.

Castle Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 29.457 subject to Rule 16b-3
09/09/2024
2
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
10/02/2024
3
Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 28.734 subject to Rule 16b-3
10/04/2024
4
AbbVie Secures FDA Approval for Parkinsons Disease Drug Vyalev
10/18/2024
5
Acquisition by Olson Tiffany of 830 shares of Castle Biosciences subject to Rule 16b-3
10/21/2024
6
Castle Biosciences Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ...
11/05/2024
7
Castle Biosciences chief commercial officer sells 124,708 in stock
11/07/2024
8
PBYI Beats Q3 Earnings Revenue Estimates, Revises 24 View, Stock Up
11/08/2024
9
Disposition of 299 shares by Derek Maetzold of Castle Biosciences at 34.15 subject to Rule 16b-3
11/12/2024
10
WASATCH ADVISORS LPs Strategic Reduction in Castle Biosciences Inc Holdings
11/14/2024
11
Disposition of 800 shares by Frank Stokes of Castle Biosciences at 30.404 subject to Rule 16b-3
11/15/2024
12
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
11/20/2024
13
Castle Biosciences Inc Shares Up 4.5 percent on Nov 22
11/22/2024
14
Castle Biosciences Inc Shares Up 3.52 percent on Nov 26
11/26/2024
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
Check out Castle Biosciences Hype Analysis, Castle Biosciences Correlation and Castle Biosciences Performance.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.93)
Earnings Share
0.21
Revenue Per Share
11.34
Quarterly Revenue Growth
0.395
Return On Assets
(0)
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.